Fundraising FoxThryvtrx
5 known investors
Find your way into Thryvtrx
Sign up to see every warm intro you have to Thryvtrx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Thryvtrx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Thryv Therapeutics is a clinical-stage biotech developing precision-medicine treatments for genetic arrhythmia syndromes and acquired cardiometabolic diseases using selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1). It is running a clinical study (Wave II) for people with Long QT Syndrome Type 2.
Founders & leadership
PF
Paul F. TruexChairman of the Board & Chief Executive OfficerPaul Truex is CEO and Chairman of Thryv Therapeutics, a clinical-stage biotech developing SGK1 inhibitors for genetic arrhythmia syndromes and cardiometabolic diseases. He previously founded Anthera Pharmaceuticals and Peninsula Pharmaceuticals, and has held business development roles at Eli Lilly including involvement with the Lilly ICOS joint venture; he holds an MBA from Indiana University and a BA in Economics from the University of Waterloo.
AS
Amy SehnertChief Medical OfficerAmy Sehnert is Chief Medical Officer at Thryv Therapeutics, a clinical-stage biotech developing precision-medicine treatments for genetic arrhythmia syndromes and cardiometabolic diseases. She is a physician-scientist with experience in clinical program development, regulatory approvals, and product launches across cardiology, genetics, maternal-fetal medicine, and oncology.
MK
Matt KilleenChief Business OfficerMatt Killeen holds a PhD in cardiac electrophysiology from Cambridge and has led R&D and strategic roles across multiple biotech companies, including BioMarin (where he built a cardiovascular disease portfolio), Renovacor (as Chief Scientific Officer, through its acquisition by Rocket Pharmaceuticals in 2022), and TikkunLev Therapeutics (as President). He is currently Chief Business Officer at Thryv Therapeutics, overseeing corporate development and cardiometabolic pipeline strategy.
Board
SD
Saumya DasChief Scientific Advisor
Investors · 5
Lumira Ventures✓ confirmed by ThryvtrxToronto · $1M – $10M
How we know: Lumira Ventures's portfolio page · the company's own site · Not right? Tell us
adMare BioInnovations✓ confirmed by ThryvtrxVancouver
How we know: the company's own site · Not right? Tell us
Related companies · 2
MedscapeMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.
UPMCUPMC is a regional healthcare provider that invests in community health through charity care, free and subsidized health programs, and support for seniors, veterans, and food-insecure populations.
Companies working in the same space as Thryvtrx.
Frequently asked questions
- What does Thryvtrx do?
- Thryv Therapeutics is a clinical-stage biotech developing precision-medicine treatments for genetic arrhythmia syndromes and acquired cardiometabolic diseases using selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1). It is running a clinical study (Wave II) for people with Long QT Syndrome Type 2.
- Who are Thryvtrx's investors?
- Thryvtrx's investors include Lumira Ventures, adMare BioInnovations, Amzak Health, CTI Life Sciences Fund L.P., Fonds de solidarité FTQ.